Inside Eli Lilly's US$27bn US Drug Manufacturing Expansion

Eli Lilly is making its biggest commitment yet to US drug manufacturing with a US$27bn plan to build four new production facilities.

The latest investment doubles the company’s domestic spending since 2020, bringing its total to more than US$50bn.

Announced at a press conference in Washington, DC, the initiative marks the largest pharmaceutical expansion in US history.

Chief Executive David Ricks describes the new locations as "mega sites," reinforcing Lilly’s ambition to meet growing demand for its medicines while strengthening the country’s pharmaceutical supply chain.

"This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality FDA-approved medicines of the future," he adds.

Expanding US pharmaceutical manufacturing

The four new sites will focus on different aspects of drug production. Three are set to manufacture active pharmaceutical ingredients (API), the key components of medicines, while the fourth will specialise in injectable drugs.

These investments will allow Lilly to "reshore" critical manufacturing capabilities, reducing reliance on overseas suppliers.

"The real gap in the supply chain in the US relates to active ingredient availability," David explains. "Importantly, two of those [facilities] will be for synthetic chemistries and these, in particular, have been absent from the landscape in the US for some time."

The company is still finalising the locations for these facilities and is in discussions with several states. Lilly expects the new sites to be fully operational within five years.

In total, the expansion will generate more than 3,000 permanent jobs for engineers, scientists, operations personnel and lab technicians.

Additionally, around 10,000 construction jobs will be created during development.

Securing supply chains and responding to market demand

Lilly's investment comes as US policymakers push for stronger domestic manufacturing.

The administration of US President Donald Trump has been vocal about reshoring critical industries and US Department of Commerce Secretary Howard Lutnick calls Lilly’s announcement "exactly what the Trump administration is all about, which is building and manufacturing and reshoring in America".

Beyond supply chain concerns, Lilly’s expansion is also a strategic response to growing market competition.

Compounding pharmacies have been able to produce copycat versions of branded drugs that are in short supply, which has affected sales of blockbuster diabetes and obesity treatments like Mounjaro and Zepbound.

By ramping up domestic production, Lilly aims to ensure steady supply and protect its market share.

Lilly has been one of the fastest-growing companies in the pharmaceutical industry. In 2024, the company reported US$11.5bn in sales for Mounjaro, while Zepbound generated US$4.9bn. Meanwhile, sales of breast cancer drug Verzenio reached US$5.3bn, marking a 37% increase from the previous year.

A long-term commitment to US investment

Lilly’s latest manufacturing expansion builds on a series of major investments in recent years.

Since 2020, the company has spent US$23bn on domestic facilities, including:

• New sites in Research Triangle Park and Concord, North Carolina
• Manufacturing plants in the LEAP Innovation District in Lebanon, Indiana
• Upgrades to facilities in Indianapolis
• Development of the Lilly Medicine Foundry in Lebanon, Indiana
• Acquisition and expansion of a manufacturing site in Kenosha County, Wisconsin

Just last year, the company pledged US$5.3bn to boost diabetes and obesity drug production in Indiana. It also committed US$3bn to expand its injectables plant in Wisconsin.

While the bulk of Lilly’s investments have been in the US, the company is also expanding its global footprint. It is spending US$1.8bn to expand production at two plants in Ireland and building a US$2.5bn manufacturing facility in Alzey, Germany, expected to begin production in 2027.

Despite its rapid growth, Lilly is not slowing down.

David believes continued investment is crucial for maintaining the company’s momentum and supporting the wider US economy.

"We believe that our investments in America and upskilling our nation's workforce will spark a significant ripple effect," he concludes.

"For every job we create, many more will be generated, positively impacting the communities that host our innovative new sites."

Explore the latest edition of Manufacturing Digital and be part of the conversation at our global conference series, Manufacturing LIVE.

Sign up to our weekly newsletter here.

Discover all our upcoming events and secure your tickets today.

Manufacturing Digital is a BizClik brand.